In a similar vein, a range of anti-cancer medications, including those that block the PI-3 K-mTOR pathway, histone deacetylases (HDAC), or topoisomerase, exhibit indirect impacts and varying degrees of effectiveness in reducing the production of and activation of HIF-1/2α [159]. The gene discussed is MTOR; the disease is cancer.